Thiamine Hydrochloride
FDA-approved product (injectable, injection), marketed as Betalin S, Thiamine Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Chronic kidney disease
- Encephalopathy
- Iron deficiency anemia
- Thiamine deficiency
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Vitamin b1, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Thiamine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Neuropathic Pain Management
NCT01263132 · start 2008-02
Registered record
- Registry ID
- NCT01263132
- Conditions
- Diabetic Neuropathies; Polyneuropathies
- Interventions
- F0434; Gabapentin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2010-02
- Enrolment
- 104
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Neuropathies; PolyneuropathiesInterventionF0434; GabapentinPhasePhase 3Registry statusCompletedEffectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
NCT00400387 · start 2006-11
Registered record
- Registry ID
- NCT00400387
- Conditions
- Abortion, Habitual
- Interventions
- Fragmin P Forte (dalteparin sodium); Multivitamin supplement
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2013-04
- Enrolment
- 449
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, HabitualInterventionFragmin P Forte (dalteparin sodium); Multivitamin supplementPhasePhase 3Registry statusCompletedTrial of Vitamins Among Children of HIV-infected Women
NCT00197730 · start 2004-06
Registered record
- Registry ID
- NCT00197730
- Conditions
- HIV Infections; Pregnancy Complications
- Interventions
- Multivitamins - vitamins B complex, C and E; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2008-05
- Enrolment
- 2,387
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Pregnancy ComplicationsInterventionMultivitamins - vitamins B complex, C and E; PlaceboPhasePhase 3Registry statusCompletedLactate Metabolism Study in HIV Infected Persons
NCT00202228 · start 2002-07
Registered record
- Registry ID
- NCT00202228
- Conditions
- HIV Infections; AIDS; Lactic Acidosis; Lipodystrophy
- Interventions
- cofactor supplementation (thiamine, riboflavin, L-carnitine)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-07
- Completion
- 2011-09
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; AIDS; Lactic Acidosis; LipodystrophyInterventioncofactor supplementation (thiamine, riboflavin, L-carnitine)PhasePhase 4Registry statusCompletedVitamin B Therapy for Hyperlactatemia
NCT00031057
Registered record
- Registry ID
- NCT00031057
- Conditions
- HIV Infections
- Interventions
- Thiamine hydrochloride; Riboflavin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionThiamine hydrochloride; RiboflavinPhaseNot applicableRegistry statusCompleted